| scholarly article | Q13442814 |
| P2093 | author name string | G Ramachandran | |
| J E Galen | |||
| M M Levine | |||
| R Simon | |||
| N Hegerle | |||
| J Bose | |||
| S M Tennant | |||
| P2860 | cites work | Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors | Q24550738 |
| O-antigen modal chain length in Shigella flexneri 2a is growth-regulated through RfaH-mediated transcriptional control of the wzy gene | Q94604168 | ||
| Designing vaccines for the twenty-first century society | Q27025703 | ||
| Pseudomonas aeruginosa O-antigen chain length is determined before ligation to lipid A core | Q28492709 | ||
| Factors contributing to the immunogenicity of meningococcal conjugate vaccines | Q28828544 | ||
| Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 | Q29615287 | ||
| Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa | Q33579987 | ||
| Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines | Q33601858 | ||
| Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates. | Q33987735 | ||
| Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam | Q34003647 | ||
| Structure and function of lipopolysaccharides. | Q34881941 | ||
| Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium | Q35098175 | ||
| Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis | Q35272921 | ||
| Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains | Q35273267 | ||
| Methodologies for Salmonella enterica subsp. enterica subtyping: gold standards and alternatives | Q35530188 | ||
| Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis | Q35783791 | ||
| Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice | Q35955978 | ||
| Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels | Q36327033 | ||
| A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design | Q36351293 | ||
| Artificial Salmonella Vaccines: Salmonella typhimurium O-Antigen-Specific Oligosaccharide-Protein Conjugates Elicit Protective Antibodies in Rabbits and Mice | Q36446367 | ||
| lfnA from Pseudomonas aeruginosa O12 and wbuX from Escherichia coli O145 encode membrane-associated proteins and are required for expression of 2,6-dideoxy-2-acetamidino-L-galactose in lipopolysaccharide O antigen. | Q36483217 | ||
| Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine | Q36970577 | ||
| Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. | Q37018107 | ||
| Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity | Q37103959 | ||
| Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates | Q37194696 | ||
| Genetics of Pseudomonas | Q37198130 | ||
| T cells control the generation of nanomolar-affinity anti-glycan antibodies | Q37730648 | ||
| Synthesis of lipopolysaccharide O-antigens by ABC transporter-dependent pathways | Q37999868 | ||
| Synthesis of bacterial polysaccharides via the Wzx/Wzy-dependent pathway. | Q38264011 | ||
| Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults | Q40420641 | ||
| Evaluation of commercially available antisera for serotyping of Pseudomonas aeruginosa | Q41236319 | ||
| The cellular level of O-antigen polymerase Wzy determines chain length regulation by WzzB and WzzpHS-2 in Shigella flexneri 2a. | Q42277297 | ||
| A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection | Q43461979 | ||
| Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of Salmonella. | Q50060625 | ||
| Regulation of Salmonella typhimurium lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz. | Q50105059 | ||
| Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines | Q50425114 | ||
| Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. | Q54572055 | ||
| Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma | Q71554787 | ||
| Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases | Q80986374 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| P433 | issue | 2 | |
| P921 | main subject | polysaccharide | Q134219 |
| P304 | page(s) | 575-585 | |
| P577 | publication date | 2018-05-15 | |
| P1433 | published in | Journal of Applied Microbiology | Q15756992 |
| P1476 | title | Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines | |
| P478 | volume | 125 |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q64095474 | Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to |
| Q90290863 | Maternal Antibodies Elicited by Immunization With an O- Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection |
| Q92170137 | Unique Regions of the Polysaccharide Copolymerase Wzz2 from Pseudomonas aeruginosa Are Essential for O-Specific Antigen Chain Length Control |
Search more.